{"disease":{"id":"post-transplant-lymphoproliferative-disease","name":"post transplant lymphoproliferative disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03131934","title":"Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT01964755","title":"Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Miami","has_results":true},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}